Results 31 to 40 of about 1,340,339 (303)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Journal for ImmunoTherapy of Cancer, 2018
Background Nivolumab, an immune checkpoint inhibitor, has revolutionized the treatment of many cancers. Due to its novel mechanisms of action, nivolumab induces a distinct profile of adverse events. Currently, the incidence and risk of developing serious
Bin Zhao, Hong Zhao, Jiaxin Zhao
doaj   +1 more source

Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events [PDF]

, 2012
An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews.ObjectivesWe set out to compare the risks of mortality and non-fatal serious adverse events in ...
Altman, Blauw, Cates, Cates, Cates, Cates, Cates, Ducharme, Giembycz, Greenstone, Lipworth, Nelson, Ni Chroinin, Ni Chroinin, Pearce, Salpeter, Sears, Walters, Walters   +18 more
core   +1 more source

Generic versus brand-name drugs used in cardiovascular diseases [PDF]

, 2016
This meta-analysis aimed to compare the efficacy and adverse events, either serious or mild/moderate, of all generic versus brand-name cardiovascular medicines.
Boccia, Stefania, D'Andrea, Elvira, Flacco Maria, Elena, Ioannidis John, Pa, Manzoli, Lamberto, Marzuillo, Carolina, Panic, Nikola, Ricciardi, Walter, Siliquini, Roberta, Villari, Paolo   +9 more
core   +1 more source

Adverse event management [PDF]

Brazilian Journal of Infectious Diseases, 2007
The Brazilian Journal of Infectious Diseases 2007;11 (5) Suppl. 1:66-70. © 2007 by The Brazilian Journal of Infectious Diseases and Contexto Publishing. All rights reserved. The treatment of hepatitis C involves combining conventional interferon (IFN) or pegylated IFN (PEG-IFN) with ribavirin (RBV).
openaire   +4 more sources

Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital

Anais Brasileiros de Dermatologia, 2022
Background: Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
William Queiroz Guimarães Wiegandt Ceglio, Marina Mattos Rebeis, Marcela Ferreira Santana, Denis Miyashiro, Jade Cury-Martins, José Antônio Sanches   +5 more
doaj   +1 more source

Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial [PDF]

, 2017
BACKGROUND/OBJECTIVES: Post-marketing comparative trials describe medication use patterns in diverse, real-world populations. Our objective was to determine if differences in rates of adherence and tolerability exist among new users to ...
Boustani, Malaz A., Callahan, Christopher M., Campbell, Noll L., Fowler, Nicole, Gao, Sujuan, Hendrie, Hugh C., Li, Lang, Perkins, Anthony J., Skaar, Todd C.   +8 more
core   +1 more source

Adverse Events Following Immunization

Zdorovʹe Rebenka, 2014
Lecture "Adverse eventsfollowing immunization"recommendedfor postgraduate education ofGeneral practitionersandpediatricians.
L.I. Chernyshova
doaj   +1 more source

Further Analyses of the Safety of Verubecestat in the Phase 3 EPOCH Trial of Mild-To-Moderate Alzheimer’s Disease [PDF]

, 2019
Background: Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events.
Aisen, Paul S., Cummings, Jeffrey L., Egan, Michael F., Furtek, Christine, Kost, James, Lines, Christopher, Mahoney, Erin, Michaelson, David, Mukai, Yuki, Stone, Julie, Tariot, Pierre N., Vellas, Bruno, Voss, Tiffini   +12 more
core   +2 more sources

Research and Discussion on the Whole Lifecycle Supervision of Typical Class Ⅱ Wound Dressing Products

Zhongguo yiliao qixie zazhi
In this study, the pre-market regulatory requirements for typical Class Ⅱ wound dressings, as well as the status of testing and post-market adverse events monitoring, were reviewed from the perspective of the whole lifecycle of medical devices ...
Lan ZHANG, Ye ZENG, Xin XIE, Jiaohui BAO, Xiaohe YANG, Weiming QI   +5 more
doaj   +1 more source

Role of assessment components and recent adverse outcomes in risk estimation and prediction:use of the Short Term Assessment of Risk and Treatability (START) in an adult secure inpatient mental health service [PDF]

, 2016
The Short Term Assessment of Risk and Treatability is a structured judgement tool used to inform risk estimation for multiple adverse outcomes. In research, risk estimates outperform the tool's strength and vulnerability scales for violence prediction ...
Dickens, Geoffrey L., O'Shea, Laura E.
core   +3 more sources